Altimmune, Inc. (NYSEARCA:ALT) Director Derace L. Schaffer acquired 6,295 shares of the stock in a transaction dated Friday, November 17th. The stock was acquired at an average cost of $2.12 per share, with a total value of $13,345.40. Following the purchase, the director now owns 227,999 shares of the company’s stock, valued at approximately $483,357.88. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Altimmune, Inc. has a 1-year low of $49.37 and a 1-year high of $54.24.

ILLEGAL ACTIVITY WARNING: “Insider Buying: Altimmune, Inc. (ALT) Director Buys 6,295 Shares of Stock” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/21/insider-buying-altimmune-inc-alt-director-buys-6295-shares-of-stock.html.

Separately, Piper Jaffray Companies started coverage on shares of Altimmune in a research note on Monday, October 9th. They issued an “overweight” rating and a $6.00 price objective for the company.

Altimmune Company Profile

iShares Diversified Alternatives Trust (the Trust) is a commodity pool. The investment objective of the Trust is to maximize absolute returns from its investments in certain futures and/or forward contracts. The Trust holds long and/or short positions in foreign currency forward contracts and exchange-traded futures contracts involving assets, such as commodities, currencies, interest rates or certain eligible stock and/or bond indices.

Receive News & Ratings for Altimmune Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune Inc. and related companies with MarketBeat.com's FREE daily email newsletter.